NAD+ vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
NAD+
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every living cell. It plays a central role in energy metabolism, DNA repair, gene expression, and cellular signaling. NAD+ levels naturally decline with age, and restoring them has become a major focus of longevity research. Injectable NAD+ bypasses the GI tract for higher bioavailability compared to oral precursors like NMN or NR.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | NAD+ | Substance P |
|---|---|---|
| Mechanism | NAD+ is a critical substrate for sirtuins (SIRT1-7), a family of enzymes involved in DNA repair, inflammation regulation, and mitochondrial function. It also serves as a coenzyme for PARP enzymes (involved in DNA damage repair) and CD38 (involved in immune cell signaling). By directly replenishing cellular NAD+ pools, injectable NAD+ supports mitochondrial electron transport chain function, enhances ATP production, and activates longevity-associated pathways. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Subcutaneous injection, typically 2–3 times per week. Start low and escalate: Twice per week protocol: Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 120 mg maintenance (0.6 ml). Three times per week protocol (e.g. Mon/Wed/Fri): Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 80 mg maintenance (0.4 ml). Volumes above assume 200 mg/ml concentration (100 mg vial reconstituted with 0.5 ml BAC water). Inject slowly — rapid administration increases flushing and nausea. Avoid back-to-back injection days. IV infusion (clinical setting): 250–750 mg per session over 2–4 hours. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Subcutaneous injection is the most practical route for self-administration. Inject slowly — rapid administration increases side effects (flushing, chest tightness, nausea). Some users split larger doses across multiple daily injections to improve tolerance. IV infusions provide the highest bioavailability but require a clinical setting. Store reconstituted NAD+ refrigerated and protect from light. NAD+ solutions are pH-sensitive; use bacteriostatic water for reconstitution. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Flushing and warmth (very common, especially at higher doses or fast injection rates). Nausea and mild GI discomfort. Chest tightness or pressure during injection (usually transient). Injection site pain or redness. Headache. These side effects are typically dose-dependent and diminish with slower administration and repeated use. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |
What They Have in Common
NAD+, Substance P are both commonly used for:
Key Differences
Unique to NAD+:
Ready to Learn More?
Looking for trusted sources?